Tyler Flores

Clinical trial advancements and a robust platform for drug discovery position Acrivon Therapeutics as a key player in precision oncology. New data offers hope for patients battling endometrial cancer.

Biotech firm Trevi Therapeutics reports strong Q3 financials and positive clinical trial data, paving the way for potential first-in-class treatment for chronic cough conditions like IPF and RCC.

Biotech firm Calidi Biotherapeutics reports positive preclinical results for its RedTail platform and lead candidate, CLD-401, alongside a successful funding round. The company aims to revolutionize cancer treatment through systemic targeted genetic medicine delivery.

Aardvark Therapeutics reports positive clinical trial progress for its Prader-Willi Syndrome treatment and unveils promising preclinical data for a novel obesity candidate designed to address limitations of existing GLP-1 RA therapies.

After navigating financial headwinds, Evofem Biosciences reports positive Q3 results, fueled by cost reductions and strategic shifts. Can the company maintain momentum and expand access to critical women’s health solutions?

Biotech firm Equillium has secured up to $50 million in funding to advance its lead candidate, EQ504, a novel therapy targeting ulcerative colitis. The company is betting on a new approach to immune modulation, shifting focus from previous programs.

Molecular diagnostics firm Co-Diagnostics reports widening losses and introduces a non-GAAP metric to assess performance, raising questions about its long-term viability as COVID-19 testing demand wanes.

Despite revenue dips, Sera Prognostics is making strides in securing Medicaid coverage for its PreTRM test, aiming to revolutionize preterm birth risk assessment and improve maternal health outcomes.

A new partnership and promising clinical data are positioning Vaxart as a key player in the emerging oral vaccine market, with implications for infectious disease prevention and global access.

Facing a historically underserved market, Daré Bioscience is pioneering a multi-pronged approach – leveraging 503B compounding, securing substantial grant funding, and developing innovative therapies – to address critical gaps in women's healthcare.

Canadian pharma firm BioSyent Inc. prepares to report Q3 & YTD 2025 earnings. A deep dive into the company's growth strategy, industry headwinds, and future outlook in the rapidly evolving specialty pharmaceutical market.

Epigenetics firm VolitionRx expands commercial reach with strategic alliances and promising financial results, navigating a competitive market with innovative diagnostic technologies.

Medical device firm GlucoTrack plans pivotal FDA submission for its fully implantable glucose monitor, boasting a three-year lifespan & direct blood glucose measurement. The company is strengthening its financial position to support upcoming trials.

Positive Phase 2 data for Elicio Therapeutics' ELI-002 7P in pancreatic cancer, combined with a bolstered cash position, positions the company for growth in the competitive immunotherapy landscape.

Clinical-stage biotech NuCana plc bolsters its cash runway to 2029 while demonstrating promising data for its ProTide cancer therapies, NUC-7738 and NUC-3373, offering hope for patients with difficult-to-treat cancers.

Spero Therapeutics’ tebipenem HBr shows promising Phase 3 results, offering a potential first-in-class oral treatment for complicated urinary tract infections and a new lifeline against antibiotic resistance.

Positive Phase 3 data and expanding applications for Reviva Pharmaceuticals’ brilaroxazine signal a potential breakthrough for schizophrenia treatment and open doors to new markets like pulmonary fibrosis and psoriasis.

QUELIMMUNE maker SeaStar Medical reports improved financials and encouraging clinical trial progress for its novel AKI prevention platform. The company is focusing on addressing a critical gap in care for acute kidney injury.

Fennec Pharmaceuticals reports strong Q3 2025 results fueled by PEDMARK®, the first FDA-approved therapy for cisplatin-induced hearing loss. Expansion into Europe and Japan signals a bright future, but supply chain vulnerabilities loom.

Profound Medical Corp. secures a key distribution agreement in Saudi Arabia as it continues to commercialize its TULSA PRO system for BPH. The company's financial position remains under scrutiny amid ongoing investment in growth.